The article by Pawlik and colleagues in this issue of Annals of Surgical Oncology provides objective data in support of a multimodality approach to the care of the pancreatic cancer patient. The current manuscript builds on the long-standing tradition of excellence in the care of this disease established by John Cameron and takes advantage of their unique institutional talents in diagnostic imaging (Elliot Fishman) and pathology (Ralph Hruban). Indeed, an obvious potential criticism of this manuscript is that they can do things at Johns Hopkins which simply can not be done elsewhere and therefore, this work is not translatable to other centers with less experience. However, we would argue that the specific results presented by Pawlik and colleagues are translatable to other less experienced centers if definitions and templates were to be developed and uniformly applied to the care of patients with pancreatic cancer throughout this country. Table  2 . Such working definitions allow for patients to be initially evaluated by physicians of any specialty and their disease extent accurately determined. 2. The treatment recommendation was altered in 24% of patients based on repeat imaging and multidisciplinary review. If we agree that for most solid tumors, treatment is stage specific, then the clinician needs to know 3 basic pieces of information to develop a treatment recommendation: histologic diagnosis, stage of disease, and performance status of the patient. The multidisciplinary Off-protocol neoadjuvant therapy (usually gemcitabine-based chemoradiation) 3. Surgery followed by protocol-based adjuvant therapy for patients who have undergone an R0/R1 resection Borderline resectable III 1. Protocol-based, stage-specific multimodality therapy 2. Off-protocol therapy usually consisting of a gemcitabine doublet followed by chemoradiation and surgery (if no disease progression) Locally advanced III 1. Protocol-based stage-specific multimodality therapy 2. Off-protocol chemoradiation if pain is uncontrolled 3. Off-protocol systemic therapy followed by chemoradiation (if no disease progression following systemic therapy) Metastatic IV 1. Protocol-based systemic therapy 2. Off-protocol systemic therapy 3. Best supportive care review/interaction (whether in an outpatient clinic or a tumor board environment) enhances crosstalk between specialties and allows for the development of consensus regarding stage-specific (and to some degree institution-specific) treatment algorithms (Table 3) . Having physicians of different specialties reach consensus on treatment recommendations requires that they have meaningful academic interchange -the multidisciplinary clinic clearly serves that purpose, but other potentially less time-consuming alternatives (multidisciplinary outpatient centers which are disease-specific not specialty-specific, weekly multidisciplinary conferences, office space allocation which considers disease orientation not just departmental affiliation) may also be available. 3. Enrollment in clinical trials was greatly enhanced by the development of the multidisciplinary clinic. Point well taken, and for a disease with such an aggressive natural history such as pancreatic cancer, attention to the enrollment of patients in clinical trials is our obligation (not our option). However, the success of such efforts is clearly influenced by the presence or absence of an academic agenda, infrastructure support for clinical trials, and patterns of reimbursement. This may be a much more complicated problem to fix for many institutions than the other two examples cited above.
Last, it is important to emphasize the value of leadership and interpersonal relationships in the success or failure of multidisciplinary disease-site program development. For those who have the group dynamics that exist among Dr. Pawlik and his colleagues (even at much smaller levels), such efforts are fun, academically stimulating, and self-perpetuating. When group dynamics are less favorable, it may be difficult to maintain consistent focus on the important goals of patient care, clinical trials, and professional and programmatic development. Dr. Pawlik and colleagues are to be congratulated for bringing objective evidence of benefit to a system of multidisciplinary care that should be made possible in many hospitals outside Baltimore.
